Renal cell carcinomas in haemodialysis patients: does haemodialysis duration influence pathological cell types and prognosis?

被引:35
|
作者
Sassa, Naoto [1 ]
Hattori, Ryohei [1 ]
Tsuzuki, Toyonori [2 ]
Watarai, Yoshihiko [3 ]
Fukatsu, Akitoshi [4 ]
Katsuno, Satoshi [5 ]
Nishikimi, Tosinori [6 ]
Fujita, Takashi [7 ]
Ohmae, Kenji [8 ]
Gotoh, Momokazu [1 ]
机构
[1] Nagoya Univ, Dept Urol, Grad Sch Med, Nagoya, Aichi 4648601, Japan
[2] Nagoya Daini Red Cross Hosp, Dept Pathol, Nagoya, Aichi, Japan
[3] Nagoya Daini Red Cross Hosp, Dept Transplant Surg, Nagoya, Aichi, Japan
[4] Komaki City Hosp, Dept Urol, Komaki, Japan
[5] Okazaki City Hosp, Dept Urol, Okazaki, Aichi, Japan
[6] Nagoya Daini Red Cross Hosp, Dept Urol, Nagoya, Aichi, Japan
[7] Chukyo Hosp, Dept Urol, Nagoya, Aichi, Japan
[8] Nagoya Mem Hosp, Dept Urol, Nagoya, Aichi, Japan
关键词
ACDK; end-stage renal disease; haemodialysis; renal cell carcinoma; renal neoplasm; CYSTIC KIDNEY-DISEASE; EPITHELIAL-CELLS; DIALYSIS PATIENTS; LLC-PK1; CELLS; ABNORMALITIES; EXPERIENCE; NEOPLASMS; TUMORS; LINE;
D O I
10.1093/ndt/gfq529
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. It is well known that renal cell carcinoma (RCC) is one of the most important complications in haemodialysis (HD) patients. However, the influence of HD duration on the development of RCCs has not yet been described. This study sought to determine whether HD duration is related to pathological RCC types and to prognosis. Methods. We examined 69 patients having HD (73 kidneys) who underwent radical nephrectomy for renal tumours between 1991 and 2008. We divided the patients into three groups according to the duration of HD (< 10 years, between 10 and 20 years, and > 20 years). All histological examinations were performed without knowledge of clinical outcomes. In each case, pathological cell types and clinical parameters were recorded. Results. The patients with HD duration of > 10 years showed distinct pathological characteristics, including acquired cystic disease of kidney-associated RCCs. The disease-free survival (DFS) rates of these groups were statistically different from one another (P < 0.05). RCC with a sarcomatoid component was found in cases having HD durations of > 10 years. The DFS rate of the patients with a sarcomatoid component was 55.9% at 5 years and 37.3% at 10 years. Conclusions. HD duration influenced pathological cell types and tumour stages of RCCs in HD patients. Patients receiving > 10 years of HD experienced RCCs with a sarcomatoid component, which resulted in poor outcomes. Hence, patients receiving long-term HD, and especially those with > 10 years of HD, should have frequent and careful medical examinations.
引用
收藏
页码:1677 / 1682
页数:7
相关论文
共 50 条
  • [1] Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis
    Josephs, Debra
    Hutson, Thomas E.
    Cowey, Charles L.
    Pickering, Lisa M.
    Larkin, James M.
    Gore, Martin E.
    Van Hemelrijck, Mieke
    McDermott, David F.
    Powles, Thomas
    Chowdhury, Paramit
    Karapetis, Chris
    Harper, Peter G.
    Choueiri, Toni K.
    Chowdhury, Simon
    BJU INTERNATIONAL, 2011, 108 (08) : 1279 - 1283
  • [2] Role of KIT expression in the prognosis of clear cell renal cell carcinomas in Chinese patients
    Zhang, Hailiang
    Ye, Dingwei
    Yao, Xudong
    Dai, Bo
    Zhang, Shilin
    Shen, Yijun
    Zhu, Yao
    Mao, Huirong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (02) : 249 - 253
  • [3] Role of KIT expression in the prognosis of clear cell renal cell carcinomas in Chinese patients
    Hailiang Zhang
    Dingwei Ye
    Xudong Yao
    Bo Dai
    Shilin Zhang
    Yijun Shen
    Yao Zhu
    Huirong Mao
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 249 - 253
  • [4] Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma
    Kobari, Yuki
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kondo, Tsunenori
    Ishida, Hideki
    Tanabe, Kazunari
    Takagi, Toshio
    IN VIVO, 2021, 35 (06): : 3585 - 3589
  • [5] Renal cell carcinoma in patients with end-stage renal disease is associated with more favourable histological features and prognosis
    Chen, Kenneth
    Huang, Hong Hong
    Aydin, Hakan
    Tan, Yeh Hong
    Lau, Weber K. O.
    Cheng, Christopher W. S.
    Yuen, John S. P.
    SCANDINAVIAN JOURNAL OF UROLOGY, 2015, 49 (03) : 200 - 204
  • [6] A novel marker ADAM 17 for clear cell renal cell carcinomas: Implication for patients' prognosis
    Li, Guorong
    Forest, Fabien
    Feng, Gang
    Gentil-Perret, Anne
    Peoc'h, Michel
    Cottier, Michele
    Mottet, Nicolas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (08) : 1272 - 1276
  • [7] Pathological findings directing immunotherapy in renal cell carcinomas
    Satici, Fadime Eda Gokalp
    Karabulut, Yasemin Yuyucu
    IMMUNOTHERAPY, 2024, 16 (04) : 199 - 204
  • [8] Does pathological stage affect the prognosis for patients with clinically staged T1 renal cell carcinoma?
    Uzzo, RG
    NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (05): : 212 - 213
  • [9] Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis
    Coimbra, Susana
    Rocha, Susana
    Nascimento, Henrique
    Valente, Maria Joao
    Catarino, Cristina
    Rocha-Pereira, Petronila
    Sameiro-Faria, Maria
    Oliveira, Jose Gerardo
    Madureira, Jose
    Fernandes, Joao Carlos
    Miranda, Vasco
    Belo, Luis
    Bronze-da-Rocha, Elsa
    Santos-Silva, Alice
    CLINICAL KIDNEY JOURNAL, 2021, 14 (05) : 1371 - 1378
  • [10] Relation of beclin-1 and bcl-2 expressions with pathological parameters and prognosis in clear cell renal cell carcinomas
    Girgin, Rabia Burcin
    Ozkanli, Seyma
    Engin-Zerk, Pinar
    Soylemez, Tuce
    Olgun, Zeynep Cagla
    Yildirim, Asif
    Kir, Gozde
    ARCHIVOS ESPANOLES DE UROLOGIA, 2022, 75 (04): : 368 - 374